Table 2.
Patient data in the Immunotherapy TMA group
| Overall (N=54) | |
|---|---|
| Age | |
| Mean (SD) | 70.9 (8.5) |
| Range | 50.0 – 89.0 |
| Sex | |
| Female | 15 (27.8%) |
| Male | 39 (72.2%) |
| Immunosuppression | |
| N | 47 (87.0%) |
| Y | 7 (13.0%) |
| IMTX agent | |
| Anti-PD-1 monotherapy | 37 (68.5%) |
| Anti-PD-1/Anti-CTLA-4 therapy | 2 (3.7%) |
| Anti-PD-L1 therapy | 15 (27.8%) |
| Viral status | |
| Positive | 28 (51.9%) |
| Negative | 22 (40.7%) |
| No data | 4 (7.4%) |
TMA cohort